<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom"><title>PeptGuru: what's changed</title><link href="https://peptguru.com/changes/"/><link rel="self" href="https://peptguru.com/changes.xml"/><id>https://peptguru.com/changes/</id><updated>2026-11-14T00:00:00Z</updated><author><name>PeptGuru editorial team (Astute Management)</name></author><entry><title>PT-141 (Bremelanotide): Regulatory update</title><link href="https://peptguru.com/peptides/pt-141-bremelanotide/"/><id>https://peptguru.com/changes/#2026-11-14-0</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites an MHRA Products database search (no UK authorisation found). An unsourced statement about the reason was removed.</summary></entry><entry><title>Liraglutide: Correction</title><link href="https://peptguru.com/peptides/liraglutide/"/><id>https://peptguru.com/changes/#2026-11-14-1</id><updated>2026-11-14T00:00:00Z</updated><summary>The safety source is now the official UK product information (Summary of Product Characteristics) for liraglutide's weight-management product, replacing an uncited monograph reference.</summary></entry><entry><title>Liraglutide: Correction</title><link href="https://peptguru.com/peptides/liraglutide/"/><id>https://peptguru.com/changes/#2026-11-14-2</id><updated>2026-11-14T00:00:00Z</updated><summary>The SCALE trial reference now carries its DOI and PubMed ID (Pi-Sunyer et al., NEJM 2015).</summary></entry><entry><title>Tirzepatide: Correction</title><link href="https://peptguru.com/peptides/tirzepatide/"/><id>https://peptguru.com/changes/#2026-11-14-3</id><updated>2026-11-14T00:00:00Z</updated><summary>The SUMMIT trial reference now carries its DOI and PubMed ID (Packer et al., NEJM 2025).</summary></entry><entry><title>AOD-9604: Correction</title><link href="https://peptguru.com/peptides/aod-9604/"/><id>https://peptguru.com/changes/#2026-11-14-4</id><updated>2026-11-14T00:00:00Z</updated><summary>A finding based on an unidentifiable early-phase source was removed, as was an unsourced toxicology statement. The Phase IIb result is now cited to its 2005 conference record and a 2026 peer-reviewed review.</summary></entry><entry><title>Semax: Correction</title><link href="https://peptguru.com/peptides/semax/"/><id>https://peptguru.com/changes/#2026-11-14-5</id><updated>2026-11-14T00:00:00Z</updated><summary>The 110-patient stroke finding is now cited to the correct study (Gusev et al., 2018). It was previously linked to a different 1997 study.</summary></entry><entry><title>Retatrutide: Correction</title><link href="https://peptguru.com/peptides/retatrutide/"/><id>https://peptguru.com/changes/#2026-11-14-6</id><updated>2026-11-14T00:00:00Z</updated><summary>Liver-fat figures corrected to the published 24-week values. Unsourced heart-rate and nausea figures removed. UK position now cites MHRA statements.</summary></entry><entry><title>Tirzepatide: Evidence update</title><link href="https://peptguru.com/peptides/tirzepatide/"/><id>https://peptguru.com/changes/#2026-11-14-7</id><updated>2026-11-14T00:00:00Z</updated><summary>SURMOUNT-5 and SUMMIT figures checked against the primary papers and corrected.</summary></entry><entry><title>Cagrilintide: Correction</title><link href="https://peptguru.com/peptides/cagrilintide/"/><id>https://peptguru.com/changes/#2026-11-14-8</id><updated>2026-11-14T00:00:00Z</updated><summary>Phase 2 trial size corrected to 706 randomised participants.</summary></entry><entry><title>Thymosin Alpha-1: Evidence update</title><link href="https://peptguru.com/peptides/thymosin-alpha-1/"/><id>https://peptguru.com/changes/#2026-11-14-9</id><updated>2026-11-14T00:00:00Z</updated><summary>The TESTS sepsis trial is now cited to its primary paper (BMJ 2025).</summary></entry><entry><title>Sermorelin: Correction</title><link href="https://peptguru.com/peptides/sermorelin/"/><id>https://peptguru.com/changes/#2026-11-14-10</id><updated>2026-11-14T00:00:00Z</updated><summary>Removed an unsourced reason for the withdrawal of Geref. The FDA record says only that it was not withdrawn for safety or effectiveness reasons.</summary></entry><entry><title>BPC-157: Correction</title><link href="https://peptguru.com/peptides/bpc-157/"/><id>https://peptguru.com/changes/#2026-11-14-11</id><updated>2026-11-14T00:00:00Z</updated><summary>Removed an unsourced statement about how BPC-157 is sold in the UK. The same unsourced statement was removed from ten other profiles.</summary></entry><entry><title>BPC-157: Regulatory update</title><link href="https://peptguru.com/peptides/bpc-157/"/><id>https://peptguru.com/changes/#2026-11-14-12</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check. Sport status confirmed from WADA's own 2026 Prohibited List (S0).</summary></entry><entry><title>TB-500: Regulatory update</title><link href="https://peptguru.com/peptides/tb-500/"/><id>https://peptguru.com/changes/#2026-11-14-13</id><updated>2026-11-14T00:00:00Z</updated><summary>Sport status confirmed from WADA's own 2026 Prohibited List (S2.3, thymosin beta-4 and its derivatives).</summary></entry><entry><title>Kisspeptin: Regulatory update</title><link href="https://peptguru.com/peptides/kisspeptin/"/><id>https://peptguru.com/changes/#2026-11-14-14</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status confirmed by a dated MHRA database check (no kisspeptin product found). WADA 2026 listing added.</summary></entry><entry><title>AOD-9604: Regulatory update</title><link href="https://peptguru.com/peptides/aod-9604/"/><id>https://peptguru.com/changes/#2026-11-14-15</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.3).</summary></entry><entry><title>CJC-1295: Regulatory update</title><link href="https://peptguru.com/peptides/cjc-1295/"/><id>https://peptguru.com/changes/#2026-11-14-16</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).</summary></entry><entry><title>Ipamorelin: Regulatory update</title><link href="https://peptguru.com/peptides/ipamorelin/"/><id>https://peptguru.com/changes/#2026-11-14-17</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.4).</summary></entry><entry><title>Sermorelin: Regulatory update</title><link href="https://peptguru.com/peptides/sermorelin/"/><id>https://peptguru.com/changes/#2026-11-14-18</id><updated>2026-11-14T00:00:00Z</updated><summary>WADA 2026 listing added (S2.2.4).</summary></entry><entry><title>Tesamorelin: Regulatory update</title><link href="https://peptguru.com/peptides/tesamorelin/"/><id>https://peptguru.com/changes/#2026-11-14-19</id><updated>2026-11-14T00:00:00Z</updated><summary>WADA 2026 listing added (S2.2.4).</summary></entry><entry><title>Semax: Regulatory update</title><link href="https://peptguru.com/peptides/semax/"/><id>https://peptguru.com/changes/#2026-11-14-20</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check.</summary></entry><entry><title>Selank: Regulatory update</title><link href="https://peptguru.com/peptides/selank/"/><id>https://peptguru.com/changes/#2026-11-14-21</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check.</summary></entry><entry><title>Epithalon: Regulatory update</title><link href="https://peptguru.com/peptides/epithalon/"/><id>https://peptguru.com/changes/#2026-11-14-22</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status now cites a dated MHRA database check.</summary></entry><entry><title>TB-500: Correction</title><link href="https://peptguru.com/peptides/tb-500/"/><id>https://peptguru.com/changes/#2026-11-14-23</id><updated>2026-11-14T00:00:00Z</updated><summary>Removed a venous-ulcer trial finding: it tested full-length thymosin beta-4, not TB-500, and cited a trial-design paper rather than the results. Some figures in it were not in the published results. The Phase 1 safety finding now cites the original study. The scoping-review finding now says plainly that direct TB-500 evidence is a single study.</summary></entry><entry><title>Teriparatide: New profile</title><link href="https://peptguru.com/peptides/teriparatide/"/><id>https://peptguru.com/changes/#2026-11-14-24</id><updated>2026-11-14T00:00:00Z</updated><summary>Teriparatide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Abaloparatide: New profile</title><link href="https://peptguru.com/peptides/abaloparatide/"/><id>https://peptguru.com/changes/#2026-11-14-25</id><updated>2026-11-14T00:00:00Z</updated><summary>Abaloparatide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Setmelanotide: New profile</title><link href="https://peptguru.com/peptides/setmelanotide/"/><id>https://peptguru.com/changes/#2026-11-14-26</id><updated>2026-11-14T00:00:00Z</updated><summary>Setmelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Afamelanotide: New profile</title><link href="https://peptguru.com/peptides/afamelanotide/"/><id>https://peptguru.com/changes/#2026-11-14-27</id><updated>2026-11-14T00:00:00Z</updated><summary>Afamelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Survodutide: New profile</title><link href="https://peptguru.com/peptides/survodutide/"/><id>https://peptguru.com/changes/#2026-11-14-28</id><updated>2026-11-14T00:00:00Z</updated><summary>Survodutide added: 4 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Mazdutide: New profile</title><link href="https://peptguru.com/peptides/mazdutide/"/><id>https://peptguru.com/changes/#2026-11-14-29</id><updated>2026-11-14T00:00:00Z</updated><summary>Mazdutide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Elamipretide: New profile</title><link href="https://peptguru.com/peptides/elamipretide/"/><id>https://peptguru.com/changes/#2026-11-14-30</id><updated>2026-11-14T00:00:00Z</updated><summary>Elamipretide added: 6 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>MOTS-c: New profile</title><link href="https://peptguru.com/peptides/mots-c/"/><id>https://peptguru.com/changes/#2026-11-14-31</id><updated>2026-11-14T00:00:00Z</updated><summary>MOTS-c added: 4 findings and 0 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>KPV: New profile</title><link href="https://peptguru.com/peptides/kpv/"/><id>https://peptguru.com/changes/#2026-11-14-32</id><updated>2026-11-14T00:00:00Z</updated><summary>KPV added: 5 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>GHRP-2: New profile</title><link href="https://peptguru.com/peptides/ghrp-2/"/><id>https://peptguru.com/changes/#2026-11-14-33</id><updated>2026-11-14T00:00:00Z</updated><summary>GHRP-2 added: 6 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>GHRP-6: New profile</title><link href="https://peptguru.com/peptides/ghrp-6/"/><id>https://peptguru.com/changes/#2026-11-14-34</id><updated>2026-11-14T00:00:00Z</updated><summary>GHRP-6 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Hexarelin: New profile</title><link href="https://peptguru.com/peptides/hexarelin/"/><id>https://peptguru.com/changes/#2026-11-14-35</id><updated>2026-11-14T00:00:00Z</updated><summary>Hexarelin added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Thymosin beta-4: New profile</title><link href="https://peptguru.com/peptides/thymosin-beta-4/"/><id>https://peptguru.com/changes/#2026-11-14-36</id><updated>2026-11-14T00:00:00Z</updated><summary>Thymosin beta-4 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.</summary></entry><entry><title>Semaglutide: Regulatory update</title><link href="https://peptguru.com/peptides/semaglutide/"/><id>https://peptguru.com/changes/#2026-11-14-37</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status re-checked against the official product information. Added two licensed uses that were missing: reducing major cardiovascular events in adults with heart disease and obesity or overweight, and weight management in adolescents aged 12 and over.</summary></entry><entry><title>Oxytocin: Regulatory update</title><link href="https://peptguru.com/peptides/oxytocin/"/><id>https://peptguru.com/changes/#2026-11-14-38</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status re-checked against the official product information. All licensed obstetric uses are now listed.</summary></entry><entry><title>Tirzepatide: Regulatory update</title><link href="https://peptguru.com/peptides/tirzepatide/"/><id>https://peptguru.com/changes/#2026-11-14-39</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status re-checked against the official product information; no change to the licensed uses.</summary></entry><entry><title>Liraglutide: Regulatory update</title><link href="https://peptguru.com/peptides/liraglutide/"/><id>https://peptguru.com/changes/#2026-11-14-40</id><updated>2026-11-14T00:00:00Z</updated><summary>UK status re-checked against the official product information. Several generic liraglutide products are now listed; adolescent weight management added to the licensed uses.</summary></entry></feed>